JP7831841B2 - コンジュゲートされたヘプシジン模倣物 - Google Patents

コンジュゲートされたヘプシジン模倣物

Info

Publication number
JP7831841B2
JP7831841B2 JP2022540618A JP2022540618A JP7831841B2 JP 7831841 B2 JP7831841 B2 JP 7831841B2 JP 2022540618 A JP2022540618 A JP 2022540618A JP 2022540618 A JP2022540618 A JP 2022540618A JP 7831841 B2 JP7831841 B2 JP 7831841B2
Authority
JP
Japan
Prior art keywords
subject
hepcidin
pharmaceutically acceptable
analog
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022540618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546878A5 (https=
JP2022546878A (ja
Inventor
ワイ リウ，デイビッド
トーマス ボーン，グレゴリー
タラナト，ルーパ
クマール グプタ，スニール
バチュラル モディ，ニシット
Original Assignee
プロタゴニスト セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロタゴニスト セラピューティクス， インコーポレイテッド filed Critical プロタゴニスト セラピューティクス， インコーポレイテッド
Publication of JP2022546878A publication Critical patent/JP2022546878A/ja
Publication of JP2022546878A5 publication Critical patent/JP2022546878A5/ja
Priority to JP2025128508A priority Critical patent/JP2025163134A/ja
Application granted granted Critical
Publication of JP7831841B2 publication Critical patent/JP7831841B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022540618A 2019-09-03 2020-09-03 コンジュゲートされたヘプシジン模倣物 Active JP7831841B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025128508A JP2025163134A (ja) 2019-09-03 2025-07-31 コンジュゲートされたヘプシジン模倣物

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962895201P 2019-09-03 2019-09-03
US62/895,201 2019-09-03
US202062983515P 2020-02-28 2020-02-28
US62/983,515 2020-02-28
US202063020945P 2020-05-06 2020-05-06
US63/020,945 2020-05-06
US202063059747P 2020-07-31 2020-07-31
US63/059,747 2020-07-31
PCT/US2020/049244 WO2021046246A1 (en) 2019-09-03 2020-09-03 Conjugated hepcidin mimetics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025128508A Division JP2025163134A (ja) 2019-09-03 2025-07-31 コンジュゲートされたヘプシジン模倣物

Publications (3)

Publication Number Publication Date
JP2022546878A JP2022546878A (ja) 2022-11-09
JP2022546878A5 JP2022546878A5 (https=) 2023-09-11
JP7831841B2 true JP7831841B2 (ja) 2026-03-17

Family

ID=74681239

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022540618A Active JP7831841B2 (ja) 2019-09-03 2020-09-03 コンジュゲートされたヘプシジン模倣物
JP2025128508A Pending JP2025163134A (ja) 2019-09-03 2025-07-31 コンジュゲートされたヘプシジン模倣物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025128508A Pending JP2025163134A (ja) 2019-09-03 2025-07-31 コンジュゲートされたヘプシジン模倣物

Country Status (16)

Country Link
US (2) US20220372099A1 (https=)
EP (2) EP4025592B1 (https=)
JP (2) JP7831841B2 (https=)
KR (1) KR20220075343A (https=)
CN (1) CN114729022A (https=)
AU (1) AU2020343328B2 (https=)
BR (1) BR112022003999A2 (https=)
CA (1) CA3152789A1 (https=)
DK (1) DK4025592T3 (https=)
ES (1) ES3058577T3 (https=)
FI (1) FI4025592T3 (https=)
IL (1) IL291030A (https=)
MX (1) MX2022002633A (https=)
PH (1) PH12022550510A1 (https=)
PL (1) PL4025592T3 (https=)
WO (1) WO2021046246A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2020014646A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
AU2022249095A1 (en) * 2021-04-01 2023-10-12 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
IL309166A (en) * 2021-06-14 2024-02-01 Protagonist Therapeutics Inc Pasidine mimesis for the treatment of hereditary hemochromatosis
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
EP4472996A4 (en) * 2022-02-02 2025-11-26 Protagonist Therapeutics Inc Conjugated hepcidin mimetics
EP4472995A4 (en) * 2022-02-02 2025-11-19 Protagonist Therapeutics Inc Conjugated hepcidin mimetics
WO2024011188A1 (en) * 2022-07-07 2024-01-11 Protagonist Therapeutics, Inc. Combination therapy for treatment of iron overload diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CZ20013018A3 (cs) 1999-03-17 2002-02-13 Novo Nordisk A/S Způsob pro acylování aminoskupiny peptidu nebo proteinu a sloučenina
US7094785B1 (en) * 2002-12-18 2006-08-22 Cornell Research Foundation, Inc. Method of treating polycythemia vera
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
EP3129040A4 (en) 2014-04-07 2018-03-21 La Jolla Pharmaceutical Company Hepdicin mimetic peptides and uses thereof
WO2015200916A2 (en) 2014-06-27 2015-12-30 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof
UA123219C2 (uk) 2015-10-23 2021-03-03 Віфор (Інтернаціональ) Аґ Інгібітори феропортину
EP3509621A4 (en) 2016-09-06 2020-06-17 La Jolla Pharmaceutical Company METHODS OF TREATING IRON OVERLOAD
WO2018128828A1 (en) * 2016-12-23 2018-07-12 Bayer Healthcare Llc Novel hepcidin mimetics and uses thereof
CA3089868A1 (en) * 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLOOD，2016年，Vol.128, No.2, pp.265-276
Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE) Version 2，ClinicalTrials.gov，2024年8月19日検索，2019年08月30日，<https://clinicaltrials.gov/study/NCT04057040?tab=history&a=2#version-content-panel>
Rusfertide (PTG-300) | Ferroportin Degrader | MedChemExpress，MedChemExpress，2024年8月22日検索，<https://www.medchemexpress.com/rusfertide.html?locale=ja-JP&srsltid=AfmBOoo3XOwxlEHc3qhW14VHSGXnBDAhXxkLheDpPRkrju0kfKDZiBCT>

Also Published As

Publication number Publication date
CA3152789A1 (en) 2021-03-11
MX2022002633A (es) 2022-06-02
AU2020343328A1 (en) 2022-04-07
US20220372099A1 (en) 2022-11-24
AU2020343328B2 (en) 2026-04-09
ES3058577T3 (en) 2026-03-11
CN114729022A (zh) 2022-07-08
FI4025592T3 (fi) 2026-01-30
JP2025163134A (ja) 2025-10-28
EP4025592B1 (en) 2025-10-29
PL4025592T3 (pl) 2026-03-16
EP4025592A1 (en) 2022-07-13
KR20220075343A (ko) 2022-06-08
EP4706671A3 (en) 2026-04-01
DK4025592T3 (da) 2026-02-09
IL291030A (en) 2022-05-01
WO2021046246A1 (en) 2021-03-11
PH12022550510A1 (en) 2023-09-04
EP4025592A4 (en) 2023-08-02
EP4706671A2 (en) 2026-03-11
BR112022003999A2 (pt) 2022-05-31
US20210061872A1 (en) 2021-03-04
JP2022546878A (ja) 2022-11-09

Similar Documents

Publication Publication Date Title
JP7831841B2 (ja) コンジュゲートされたヘプシジン模倣物
US12269856B2 (en) Hepcidin analogues and uses thereof
US11472842B2 (en) Analogues of hepcidin mimetics with improved in vivo half lives
JP2026048851A (ja) コンジュゲートされたヘプシジン模倣物
JP7849383B2 (ja) コンジュゲートされたヘプシジン模倣物
KR20170043509A (ko) 헵시딘 및 미니-헵시딘 유사체 및 그의 용도
TW202304951A (zh) 結合鐵調素模擬物
WO2022212698A1 (en) Conjugated hepcidin mimetics
EA048412B1 (ru) Конъюгированные миметики гепсидина

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241126

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20241216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241216

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260226

R150 Certificate of patent or registration of utility model

Ref document number: 7831841

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150